One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

Novartis NOVN1.90%increase; green up pointing triangle forecasts further profit and sales growth this year after beating analysts’ expectations in the fourth quarter of 2024, despite looming ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that could reach up to $1 billion in biobucks. The San Diego-based biotech ...

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...

2. Please see detailed guidance assumptions on page 7. 3. As defined on page 35 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, ...